<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02564744</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 1562-201</org_study_id>
    <secondary_id>2015-004061-87</secondary_id>
    <nct_id>NCT02564744</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multicenter, non-randomized phase 2 (with safety run-in phase)
      clinical study. The study will consist of a screening period, a treatment period, an end of
      treatment visit, and a follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>up to 20 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 20 months</time_frame>
    <description>Number of participants with clinical responses as assessed by Lugano Classification of response assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma drug concentration (Cmax) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time-concentration curve from time 0 to t (AUC0-t) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time-concentration curve from time 0 to infinity (AUC0-inf) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Debio 1562 and Rituximab</measure>
    <time_frame>Pre-dose and within 5 minutes of drug infusion, on Day 1, 2, 3, 8, 15 for Cycles 1 and 3; and on Day 1 for Cycles 2 and 4 through 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 20 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with presence of human anti-drug antibody (ADA) for Debio 1562</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1 to 8; and at the end of treatment (Up to Month 36) and 30-day follow-up visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Safety run-in</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a diagnosis of relapsed and/or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma (FL), Marginal Zone/Mucosa-associated Lymphoid Tissue (MZ/MALT), Mantle Cell Lymphoma (MCL) or other Non-Hodgkin's Lymphoma (NHL) with the Sponsor's approval, will receive Debio 1562 and Rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a diagnosis of R/R DLBCL (de novo or transformed) will receive Debio 1562 and Rituximab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2- Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with a diagnosis of R/R FL, MZ/MALT, or other subtypes of NHL will receive Debio 1562 and Rituximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Debio 1562</intervention_name>
    <description>Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle.</description>
    <arm_group_label>Safety run-in</arm_group_label>
    <arm_group_label>Phase 2- Cohort 1</arm_group_label>
    <arm_group_label>Phase 2- Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be given on the same day as Debio 1562, Q3W IV at a dose of 375 mg/m^2 on Day 1 of a 21-day cycle.</description>
    <arm_group_label>Safety run-in</arm_group_label>
    <arm_group_label>Phase 2- Cohort 1</arm_group_label>
    <arm_group_label>Phase 2- Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed R/R DLBCL, FL, marginal zone lymphoma (MZL)/MALT, MCL, or
             other Sponsor approved NHL subtypes.

          -  Participants must have evaluable or measurable disease in accordance with the
             International Working Group Guidelines for Lymphoma.

          -  Participants must have received at least one but no more than six prior treatment
             regimens. Prior treatment with an anti-CD20 agent, either alone or in combination, is
             allowed.

          -  Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status 0
             - 2.

          -  Participants who are Hepatitis B surface antigen positive (HBsAg+) (must be PCR
             negative) who are taking antivirals, are allowed.

        Exclusion Criteria:

          -  Participants with a diagnosis of chronic lymphocytic leukemia (CLL) or small
             lymphocytic lymphoma (SLL).

          -  Participants with active hepatitis A, B or C infection or other uncontrolled
             intercurrent illness.

          -  Women who are pregnant or breast feeding.

          -  Participants who have received prior therapy with other anti-CD37-targeting antibody
             drug conjugate.

          -  Participants who have known central nervous system, meningeal, or epidural disease
             including brain metastases.

          -  Participants with impaired cardiac function or clinically significant cardiac disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Debiopharm International S.A</last_name>
    <phone>+41 21 321 01 11</phone>
    <email>clinicaltrials@debiopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alabama Oncology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Smilow Cancer Center at Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mcfarland Clinic PC</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novant Health Oncology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Healthcare System</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur asbl - Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jan Yperman Ziekenhuis</name>
      <address>
        <city>Ieper</city>
        <state>West-Vlaanderen</state>
        <zip>8900</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

